SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desks steep slide to multi-year lows is drawing attention amid concerns about weaker ad spending, slowing growth and competition from Amazon and other platforms. Traders are largely criticizing management and CEO compensation, while bullish voices argue the cash-rich company is oversold and could rebound; others expect more downside without evidence of a turnaround.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A pause in the federal cannabis-rescheduling hearing, with the judge asking the DEA to respond to a report on gaps in drug-scheduling procedures, has renewed uncertainty around the timing of a Schedule III recommendation. Traders are split between viewing the move as a limited procedural delay and worrying that it could prolong the process, with some calling the selloff an overreaction.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, drove a sharp rally. Traders were broadly bullish and discussed a possible short squeeze and upcoming lung-cancer data, while others warned the run-up could invite profit-taking or share dilution.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

The FHFAs move to include VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing has raised concerns that competition could weaken FICOs longstanding mortgage-scoring advantage, driving a sharp selloff. Traders are divided between viewing the change as a serious threat to FICOs pricing power and moat, and arguing that the market is overreacting because FICO remains entrenched; many are also debating whether the drop is a buying opportunity or a falling knife.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment and clinical collaboration around ivonescimab are driving attention, with traders welcoming the added financing and pharma validation while others weigh dilution and stress that the deal is not a buyout. Discussion also points to the upcoming FDA decision as a separate, uncertain catalyst.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings selloff is prompting debate over competition from Kalshi and Polymarket and the cost of building its own prediction-market business, DKeX. Bears worry the platforms are taking wagering share and that higher investment will weigh on margins; bulls point to DKeXs reported volume growth and argue DraftKings could benefit whether prediction markets expand or face tighter state regulation.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

ICP is drawing attention after a sharp rebound and a push through a key technical resistance level, with traders debating whether the move can hold or will fade. Bullish holders also point to reported Pakistan government app deployments and ICPs decentralized cloud and AI infrastructure, while skeptics question adoption and the rallys staying power.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieves addition to the S&P Total Market and S&P Completion indices is driving attention, with traders viewing index-related demand as supportive and reacting bullishly. The optimism is tempered by profit-taking and uncertainty over the timing of the DEA judges recommendation on cannabis rescheduling.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns quarterly earnings report is the main focus, with traders weighing whether AI-driven HBM and DRAM demand, tight supply, and firm pricing will support results and forward guidance. Bulls expect continued strength, while skeptics cite the stocks run-up and memorys cyclical risks, debating whether even a strong report could trigger a selloff.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

QURE is selling off after four-year AMT-130 data showed a weaker, statistically nonsignificant effect on Huntingtons disease progression than the stronger three-year results, raising concerns about durability. Traders are split: some see an overreaction because the BLA is based on the three-year data, while others question whether the treatments benefit holds over time.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know  

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?

Key PointsCRISPR Therapeutics has two important data readouts coming up soon...

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close.

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsCRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY...

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Equity

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $59.03 in the latest trading session, marking a +1.2% move from the prior day.

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

Key PointsEven if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year...

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?

Key PointsCRISPR Therapeutics will likely be a much larger company in 10 years...

Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Bearish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRSP News